Abstract
Neuroimaging studies of cholinesterase inhibitor (ChEI) treatment in Alzheimers disease (AD) have shown the different short and long term actions of ChEIs. fMRI studies of the ChEI donepezil have focused on its short to medium term action without exploring the effects of established treatment. In this exploratory study the effect of 20 weeks donepezil treatment on regional brain activity was measured with fMRI in patients with mild AD. Twelve patients with probable AD and nine age-matched controls were assessed with a Pyramids and Palm Trees semantic association fMRI paradigm and an n-back working memory fMRI paradigm. In the patient group only, the assessment was repeated after 20 weeks of treatment. After treatment, differences from normal healthy elderly became more pronounced. There was also a spread of deactivation which at retest was detectable in task relevant areas. Behaviourally, however, there were no significant differences between group baseline and retest scores, with a range of performance probably reflecting variation in drug efficacy across patients. Parametric analyses established that increased behavioural scores at retest correlated significantly with higher activation levels in non task relevant areas. Behavioural stability with donepezil treatment was not paralleled by the pattern of improved task specific brain activation reported in similar studies of other ChEIs. This is arguably related to the different mechanisms of action of the ChEIs and might be a clinical correlate of the reported synaptic upregulation following long term donepezil treatment.
Keywords: fMRI, semantic, working memory, upregulation, pharmacodynamic
Current Alzheimer Research
Title: Established Donepezil Treatment Modulates Regional Brain Activation in Early Alzheimers Disease
Volume: 7 Issue: 5
Author(s): W.J. McGeown, M.F. Shanks, K.E. Forbes-McKay, G.D. Waiter, I. Elrick, M.G. Venneri and A. Venneri
Affiliation:
Keywords: fMRI, semantic, working memory, upregulation, pharmacodynamic
Abstract: Neuroimaging studies of cholinesterase inhibitor (ChEI) treatment in Alzheimers disease (AD) have shown the different short and long term actions of ChEIs. fMRI studies of the ChEI donepezil have focused on its short to medium term action without exploring the effects of established treatment. In this exploratory study the effect of 20 weeks donepezil treatment on regional brain activity was measured with fMRI in patients with mild AD. Twelve patients with probable AD and nine age-matched controls were assessed with a Pyramids and Palm Trees semantic association fMRI paradigm and an n-back working memory fMRI paradigm. In the patient group only, the assessment was repeated after 20 weeks of treatment. After treatment, differences from normal healthy elderly became more pronounced. There was also a spread of deactivation which at retest was detectable in task relevant areas. Behaviourally, however, there were no significant differences between group baseline and retest scores, with a range of performance probably reflecting variation in drug efficacy across patients. Parametric analyses established that increased behavioural scores at retest correlated significantly with higher activation levels in non task relevant areas. Behavioural stability with donepezil treatment was not paralleled by the pattern of improved task specific brain activation reported in similar studies of other ChEIs. This is arguably related to the different mechanisms of action of the ChEIs and might be a clinical correlate of the reported synaptic upregulation following long term donepezil treatment.
Export Options
About this article
Cite this article as:
McGeown W.J., Shanks M.F., Forbes-McKay K.E., Waiter G.D., Elrick I., Venneri M.G. and Venneri A., Established Donepezil Treatment Modulates Regional Brain Activation in Early Alzheimers Disease, Current Alzheimer Research 2010; 7 (5) . https://dx.doi.org/10.2174/156720510791383877
DOI https://dx.doi.org/10.2174/156720510791383877 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Point of View: The Need to Identify an Antigen in Psyconeuroimmunological Disorders
Current Pharmaceutical Design Immunotherapy of Melanoma
Current Molecular Pharmacology Lipoprotein Like Nanoparticles Used in Drug and Gene Delivery
Current Pharmaceutical Design Cashew Gum A Versatile Hydrophyllic Polymer: A Review
Current Drug Therapy Biophysical Analysis of the Transition of an all α-Helical Greek-Key Protein into Amyloid Fibrils Composed of β-Sheet Structure
Protein & Peptide Letters Therapy Stratifications and Novel Approach in Pursuit of Aids Related Kaposi’s Sarcoma Management- A paradigm for Non Invasiveness
Current Drug Delivery Impacts and Concerns for vCJD in Blood Transfusion: Current Status
Current Molecular Medicine Cytochromes P450 in the Bioactivation of Chemicals
Current Topics in Medicinal Chemistry Flavonoids as Acetylcholinesterase Inhibitors
Current Medicinal Chemistry Advanced Mass Spectrometry-Based Methods for the Analysis of Conformational Integrity of Biopharmaceutical Products
Current Pharmaceutical Biotechnology Pathogenesis of and Therapeutic Strategies to Ameliorate the Transthyretin Amyloidoses
Current Pharmaceutical Design Reducing Gabaergic Inhibition Restores Cognitive Functions in a Mouse Model of Down Syndrome
CNS & Neurological Disorders - Drug Targets Long-Chain Omega-3 Fatty Acid Deficiency in Mood Disorders: Rationale for Treatment and Prevention
Current Drug Discovery Technologies Prevalence and Prognostic Value of Depression and Anxiety in Patients with Diabetic Foot Ulcers and Possibilities of their Treatment
Current Diabetes Reviews Possible Molecular Interactions of Bexarotene - A Retinoid Drug and Alzheimer's Aβ Peptide: A Docking Study
Current Alzheimer Research Recent Advances in Medicinal Chemistry to Treat Filariasis and Helminthiasis
Current Topics in Medicinal Chemistry Pharmacogenetics and Drug Therapy in Psychiatry - The Role of the CYP2D6 Polymorphism
Current Pharmaceutical Design Programmed Cell Death Mechanisms in Neurological Disease
Current Molecular Medicine Lower Financial Status and Adherence to Medication Determines 10-Year (2004-2014) All-Cause Mortality and Risk for Acute Coronary Syndrome Incidence Among Cardiac Patients: the GREECS Study
Current Vascular Pharmacology Types of Voltage-Gated Calcium Channels: Molecular and Electrophysiological Views
Current Hypertension Reviews